Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07685548 | AI-Driven Tumor Response Evaluation for Solid Tumors | not yet recruiting | — | 6,120 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06117891 | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery(REFINE-IO) | active not recruiting | — | 300 | BayerINDUSTRY |
| 12 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT06342414 | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer(ELUCIDATE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 2 | Jul 7, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07675187 | HCC Risk and Monitoring in Patients With Type 2 Diabetes(GAAD-DM) | not yet recruiting | N/A | 2,400 | National Taiwan University HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687758 | Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score(HCV-aMAP) | completed | — | 571 | Siriraj HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 50 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT04523493 | Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | active not recruiting | Phase 3 | 530 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 5 | Jul 6, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684040 | A Study of Combination Therapy in Patients With Resectable Liver Cancer(Archer) | not yet recruiting | Phase 2 | 68 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07685535 | HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 29 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT02088775 | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | completed | N/A | 44 | Fox Chase Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02344680 | Liver Fibrosis in Zambian HIV-HBV Co-infected Patients | completed | — | 349 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03186898 | Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer | active not recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | active not recruiting | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06101277 | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)(LIVELONG) | recruiting | N/A | 300 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06184152 | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06260943 | Targeted Navigation in Hepatocellular Carcinoma (HCC) | recruiting | N/A | 210 | University of MiamiOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07681817 | Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer | not yet recruiting | N/A | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01862315 | Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) | completed | Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07265271 | Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)(CENTINEL) | recruiting | — | 600 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07658586 | AI Multimodal Model for Liver Cancer Diagnosis and Prognosis(AIM-LCAP) | active not recruiting | — | 600 | Guangxi Medical UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679061 | First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) | recruiting | — | 200 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
| NCT04294498 | Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | completed | Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04740307 | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | completed | Phase 2 | 116 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Jun 30, 2026 | clinicaltrials |
| NCT04962958 | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | completed | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 30 | Coherus Oncology, Inc.INDUSTRY | 4 | Jun 29, 2026 | clinicaltrials |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07019844 | PSMA PET for the Staging and Management of Hepatocellular Carcinoma | recruiting | — | 90 | VA Office of Research and DevelopmentFED | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07110233 | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma | not yet recruiting | N/A | 64 | University of California, San FranciscoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06824974 | Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer(TRE+HE) | recruiting | N/A | 50 | University of California, San DiegoOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 59 | Devalingam MahalingamOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07669597 | Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag(HCC) | active not recruiting | — | 50 | Sohag Oncology CenterOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 3 | 356 | National Cancer Institute (NCI)NIH | 3 | Jun 24, 2026 | clinicaltrials |
| NCT01715402 | Optimization of Health Expenditure in Liver Surgery | completed | — | 3,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials